Extended Data Fig. 11: Transcriptomic and proteomic analysis of leukaemia in the absence of TAUT.
From: Taurine from tumour niche drives glycolysis to promote leukaemogenesis
a, Top 20 upregulated pathways in −/− time matched bcCML cells as compared to +/+ controls. b, Heatmap of glycolysis associated genes in bcCML samples. c, GSEA showing downregulation of genes associated with Myc and mTORC1 pathways on TauT loss (a-c, n = 3 animals per cohort). d, Relative expression of glycolysis associated genes in +/+ and −/− Lin− bcCML cells (mean ± s.d.; n = 3 technical replicates per cohort). e, Western blot shows phospho-mTOR (pmTOR), mTOR, phosopho-p70S6k (p-p70S6K), p70S6K, and actin protein expression in +/+ and −/− Lin− bcCML cells (also see Fig. 5k–m, n = 4 independent disease end point samples/cohort). f, Volcano plot of global proteome (upper panel) and phosphoproteome (bottom panel) with differential abundance in +/+ and −/− leukaemia cells from time matched recipients (n = 5 animals per cohort). g, Normalized abundance of mTOR pathway proteins (mean ± s.e.m.; n = 5 animals per cohort; unpaired two-tailed Student’s t-test). h, Expression of glycolysis related genes in +/+ Lin− bcCML treated with indicated doses of TAG for 72 h (mean ± s.d.; n = 3 technical replicates per cohort). i, Expression of glycolysis related genes in +/+ Lin− bcCML treated with 1 mM GES for 72 h (mean ± s.d.; n = 3 technical replicates per cohort).
